Eden Research plc Director/PDMR Shareholding (7997G)
28 Julio 2021 - 8:53AM
UK Regulatory
TIDMEDEN
RNS Number : 7997G
Eden Research plc
28 July 2021
28 July 2021
Eden Research plc
("Eden" or "Company")
Director/PDMR Shareholding
Eden Research plc (AIM: EDEN), the AIM-quoted company focused on
sustainable biopesticides and plastic-free formulation technology
for use in global crop protection, animal health and consumer
products industries, announces that Sean Smith, CEO, has purchased
180,000 shares in Eden at a price of GBP0.10 per share.
Following the transaction outlined above, Mr. Smith's interest
in the share capital of the Company is 911,039 Ordinary Shares
representing 0.24 per cent. of the Company's issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
For further information contact:
www.edenresearch.com
Eden Research plc
Sean Smith
Alex Abrey 01285 359 555
Cenkos Securities plc (Nominated advisor
and broker)
Giles Balleny / Camilla Hume/ Mark Connelly
(corporate finance)
Michael Johnson (sales) 020 7397 8900
Hawthorn Advisors (Financial PR)
Lorna Cobbett / Victoria Ainsworth eden@hawthornadvisors.com
1 Details of the person discharging managerial responsibilities / person closely associated
--- -----------------------------------------------------------------------------------------------
a) Name Sean Smith
--- ------------------------------------------------------------- --------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------------------------------------------- --------------------------------
b) Initial notification /Amendment Initial Notification
--- ------------------------------------------------------------- --------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------------------------------------------
a) Name Eden Research plc
--- ------------------------------------------------------------- --------------------------------
b) LEI 213800ZWTYTVQQSM3J85
--- ------------------------------------------------------------- --------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--- -----------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument Ordinary shares of 1 pence each
Identification code
GB0001646941
--- ------------------------------------------------------------- --------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
--- ------------------------------------------------------------- --------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
--------- ----------
10.00p 180,000
--------- ----------
--- ------------------------------------------------------------- --------------------------------
d) Aggregated information
- Aggregated volume
- Price N/A
--- ------------------------------------------------------------- --------------------------------
e) Date of the transaction 28 July 2021
--- ------------------------------------------------------------- --------------------------------
f) Place of the transaction LSE, AIM Market (XLON)
--- ------------------------------------------------------------- --------------------------------
Notes to Editors:
Eden Research is an AIM quoted company that develops and
supplies breakthrough biopesticide products and natural,
plastic-free microencapsulation technologies to the global crop
protection, animal health and consumer products industries.
Eden's Sustaine(R) encapsulation technology is used to harness
the biocidal efficacy of naturally occurring chemicals produced by
plants (terpenes) and can also be used with both natural and
synthetic compounds to enhance their performance and ease-of-use.
Sustaine microcapsules are naturally derived, plastic-free,
biodegradable micro-spheres derived from yeast extract. It is one
of the only viable, proven and immediately registerable solutions
to the microplastics problem in formulations requiring
encapsulation.
Eden has numerous patents and a pipeline of products at
differing stages of development targeting specific areas of the
global agrochemicals industry. Eden was admitted to trading on AIM
in May 2012.
For more information about Eden, please visit:
www.edenresearch.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSEFFDAEFSEIW
(END) Dow Jones Newswires
July 28, 2021 09:53 ET (13:53 GMT)
Eden Research (LSE:EDEN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Eden Research (LSE:EDEN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
